Emergent BioSolutions (EBS) Operating Income (QoQ) (2011 - 2026)
Emergent BioSolutions (EBS) Operating Income (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.63% |
| Dec 31, 2025 | -136.47% |
| Sep 30, 2025 | 4,681.25% |
| Jun 30, 2025 | -96.79% |
| Mar 31, 2025 | 625.26% |
| Dec 31, 2024 | -114.73% |
| Sep 30, 2024 | 131.70% |
| Jun 30, 2024 | -611.31% |
| Mar 31, 2024 | 190.87% |
| Dec 31, 2023 | 81.91% |
| Sep 30, 2023 | 17.34% |
| Jun 30, 2023 | -98.44% |
| Mar 31, 2023 | -166.91% |
| Dec 31, 2022 | -22.08% |
| Sep 30, 2022 | 40.63% |
| Jun 30, 2022 | -1,205.80% |
| Mar 31, 2022 | -97.59% |
| Dec 31, 2021 | 741.61% |
| Sep 30, 2021 | -729.58% |
| Jun 30, 2021 | -92.30% |